ArticleCureus2025
Antibody Positive Miller-Fisher Syndrome and Acute Motor Sensory Axonal Neuropathy With Respiratory Failure: A Rare Overlap.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Miller-Fisher syndrome (MFS), a rare variant of Guillain-Barré syndrome (GBS), is classically defined by ophthalmoplegia, ataxia, and areflexia and is strongly associated with anti-GQ1b antibodies. We report a 35-year-old man presenting with classical MFS features who rapidly deteriorated with progressive limb weakness and respiratory failure requiring mechanical ventilation. Cerebrospinal fluid analysis showed albuminocytologic dissociation, while nerve conduction studies were consistent with an axonal process. Serologic testing revealed positivity for both anti-GQ1b and anti-GD1a antibodies, confirming an overlap between MFS and acute motor sensory axonal neuropathy (AMSAN). The patient showed marked neurological recovery following intravenous immunoglobulin therapy and intensive supportive care. This case highlights a rare MFS-AMSAN overlap with respiratory failure and underscores the importance of early recognition, vigilant respiratory monitoring, and prompt immunotherapy in preventing morbidity and optimizing patient outcomes in rapidly progressive GBS-spectrum disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.